RATIONALE: Inhaled lipopolysaccharide (LPS) challenges are frequently used as models of neutrophilic airway inflammation against which to test potential therapies for airway disease. Treatment efficacy is best assessed through the examination of inflammatory responses in induced sputum. However, sputum inductions are not often feasible and also impractical in the clinical setting, necessitating the identification of correlative biomarkers. This study, therefore, examines whether systemic neutrophilic inflammatory responses, which are easily obtained via blood samples, correlate with LPS-induced airway inflammatory responses. METHODS: A total of 130 inhaled LPS challenges using 20,000 endotoxin units of Clinical Center Reference Endoxin were conducted over the course of 7 studies in both healthy volunteers (n597) and mild asthmatics (n533). Induced sputum and peripheral blood were obtained before LPS (pre-LPS) challenge and 6 hours after LPS challenge (post-LPS). The change in percent neutrophils (D%PMNs) in pre-LPS to post-LPS sputum and peripheral blood samples was calculated. Spearman correlation coefficients (r) were then determined to evaluate the linear association between these outcomes. RESULTS: Seventy percent of the total population (91/130) was identified as LPS responders, defined as having a D%PMNs > _ 10. No significant correlation between D%PMNs in sputum vs peripheral blood was found in the total population (r50.10; p50.26) or in the total population stratified by asthma status (asthmatics: r5-0.07; p50.72; non-asthmatics: r50.16; p50.14) and by LPS responder status (r50.11; p50.30). CONCLUSIONS: Systemic neutrophilic inflammatory responses do not correlate with LPS-induced airway inflammatory responses. Future work should focus on identifying other potential readily-obtainable biomarkers that correlate with LPS-induced neutrophilic airway inflammation. Department of pediatrics, Chang Gung Memorial Hospital, Taoyuan Hsien, Taiwan. RATIONALE: CC 10 has been shown to play an important protective role in different models of respiratory inflammatory diseases, but its putative receptor and mechanisms of actions remain incompletely defined. To this end, the potential involvement of a low-affinity receptor for formyl peptide, FPRL1, in mediating CC10's anti-inflammatory effects was evaluated in mouse lung fibroblasts and human neutrophils. METHODS: The functional effects of CC10 on FPRL1 agonist-induced cytokine secretion in mouse fibroblasts and superoxide generation in human neutrophils were determined using PCR, ELISA and Flow Cytometry. In addition, the inhibitory activity of CC10 on the AA/COX-2 pathway and release of inflammatory lipid mediators in LPS-induced neutrophils was determined by Western blotting and ELISA. RESULTS: Using labeled CC10 and serum amyloid peptide (SAA; an FPRL1 agonist), significant and saturable bindings of the respective labeled ligands were found in FPRL1, but not mock-transfected, cells.
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Functionally, CC10 was able to dose-dependently suppress the expression of SAA-or IL-13-induced TGF-b1 in mouse pulmonary fibroblasts. In human neutrophils from 12 subjects, it was shown that CC10 significantly suppressed the superoxide production induced by an FPRL1 agonist (WKYMVM peptide), but not the fMLF peptide. Moreover, functional studies revealed that fMLP-induced expression of COX-2 synthase was significantly inhibited by CC10, resulting in significantly reduced levels of AA metabolites, including PGE2, in neutrophils. CONCLUSIONS: In this study, CC10 was shown to be able to antagonize the lung fibroblast and human neutrophil responses through its interaction with FPRL1 and its modulatory activity on the AA metabolic pathway. We hypothesized that the change of Th17 and Th17/Treg ratio is associated with AHR in asthmatic children. METHODS: Twenty allergic asthma patients and 20 healthy control subjects were enrolled in this study. The diagnosis of asthma was made according to the criteria of Global Initiative for Asthma (GINA). PEF% pred, FEV 1 % pred and FEV 1 /FVC ratio were measured. Methacholine bronchial provocation test (MBPT) was performed using graded concentrations at 0.4, 1.6, 6.4, and 12.8 mg/ml until 20% reduction of FEV 1 . Flow cytometry was used to determine % of Th17 and Treg from peripheral blood mononuclear cells. Serum levels of IL-17A and IL-10 were assessed by ELISA. RESULTS: Th17 cells and Th17/Treg ratio were significantly increased in asthmatic children (2.27 6 0.21% and 0.37 6 0.039) than control group (1.19 6 0.13% and 0.18 6 0.02), P＜0.01 for both. Although not statistically significant, PEF% pred and Th17/Treg ratio showed trend of correlation CONCLUSIONS: Allergic asthma children demonstrated correlation between elevated Th17, Th17/Treg ratio and AHR. Th17 and Th17/Treg ratio could be used to monitor disease progress and as therapeutic targets.
